Indian markets ended near day's highs on Tuesday

	Dated:31 May,2011

Market Round-up SENSEX 18503.28 271.22 NIFTY 5560.15 87.05 NASDAQ 2141.54 17.78 DJIA 10060.06 19.61 RS/$ 46.79 -0.14 NSE Gainers Scrip Price(Rs.) %Change Essar Ports Ltd. 124.00 + 30.60 Jenson & Nicholson (India 4.95 + 20.73 KDL Biotech Ltd. 7.65 + 20.47 Rajapalayam Mills Ltd. 613.45 + 20.00 Orissa Minerals Developme 53,639.30 + 20.00 NSE Losers Scrip Price(Rs.) %Change Smartlink Network Systems 66.25 -34.37 Sanghvi Forging & Enginee 77.50 -19.98 Paramount Printpackaging 19.50 -19.59 Ashapura Minechem Ltd. 20.15 -11.62 Nicco Corporation Ltd. 2.15 -10.42

Top Headlines Nifty ends above 5550; JPAsso, ACC, Grasim, DLF up Indian markets ended near day's highs on Tuesday as investors bought stocks across the board following rally in global equities. Expect fresh triggers in market in 2-3 months: Reliance MF In an interview with ET Now, Sunil Singhania, Deputy Head-Equities, Reliance Mutual Fund, talks about the market and their current portfolios. GDP numbers may affect market negatively in short term: BNP Paribas Securities Manishi Raychaudhuri, MD & HOR, BNP Paribas Securities, talks to ET Now on how the markets are likely to take GDP data points. Views on Stocks/Markets Avoid Punj Lloyd: Sudarshan Sukhani Avoid GVK Power: Sudarshan Sukhani Mundra remains a buy: Sudarshan Sukhani IPO/Global Markets World stocks rise Asian stocks mostly rise European stocks advance at open Rupee / Gold Gold demand weak Re gains 13p versus dollar Gold holds near 4-week high More 'Market' News Infosys says brand value rose 12% to $8.87 bn in FY11; stock up Infy said its brand value climbed 12% during the year-ended March 2011 to nearly $8.87 bn despite ongoing allegations of visa misuse in the US. Coal India earmarks over Rs 10,000 crore capex for FY-12; stock up CIL has earmarked an over Rs 10K cr capital expenditure for the current fiscal on capacity expansion and acquisitions that are likely to be completed. Buy or Sell: Does financial services foray augur well for Piramal Healthcare? Drugmaker Piramal Healthcare, which announced financial services foray earlier this month, has drawn a flak from analysts and investors.